Overview

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial was to determine the efficacy and safety of linaclotide 72 ug administered once daily to patients with chronic idiopathic constipation (CIC). The primary efficacy parameter is the percentage of participants in each dosing group that meet the protocol definition for complete spontaneous bowel movement (CSBM) Overall Responder.
Phase:
Phase 3
Details
Lead Sponsor:
Ironwood Pharmaceuticals, Inc.
Collaborator:
Forest Laboratories
Treatments:
Linaclotide